Medtronic IN.PACT (DCB)

PreclinicalSmall molecule

SShockwave Medical, Inc.

Medtronic IN.PACT (DCB) is one of 12 small molecule programs targeting Shock. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ShockCompleted

ShockPreclinical

Completed

Competition

Competitive Landscape

12 competitors in Shock

#DrugCompanyPhaseTrials

Dobutrex

Eli Lilly

Approved

1 2

Intropin

Pfizer

Approved

—3

Giapreza

LLa Jolla Pharmaceutical Company

Approved

2 4

Adrenaline

SSamson Clinical Operations Pty Ltd

Approved

1 5

Pitressin

AAultman Health Foundation

Approved

1 6

Nitrostat

VViatris Specialty LLC

Approved

—7

Heparin Sodium

BBaxter Healthcare Corporation

Jardiance

Cyklokapron

Cancidas

FFresenius Kabi Taiwan Ltd.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Shock1 trial

Shockwave Medical Peripheral Lithoplasty System Study for PAD (Disrupt PAD III)

Completed·SShockwave Medical, Inc.·N/A·NCT02923193·306 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Medtronic IN.PACT (DCB). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Medtronic IN.PACT (DCB) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Medtronic IN.PACT (DCB). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shockwave Medical, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: SShockwave Medical, Inc.

Medtronic IN.PACT (DCB)

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Shock1 trial

References

Drug Info

Quick Facts

Related News